1,4-Dichlorobenzene

Name: 1,4-Dichlorobenzene
Brand: MedChemExpress
SKU: HY-Y0496
Rating: 4.5 (1 reviews)

Cat. No.: HY-Y0496 Purity: 99.71%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

1,4-Dichlorobenzene is a non-genotoxic, orally active mitogenic/tumor-promoting carcinogen that is also widely used as a dye, resin intermediate, and deodorant, moth repellent/insecticide. 1,4-Dichlorobenzene induces liver tumors in mice and promotes the growth of spontaneous precancerous lesions, but shows no liver tumor-inducing activity in F344 rats. Exposure to 1,4-dichlorobenzene leads to elevated leukocyte counts, serum alanine aminotransferase, and blood urea nitrogen levels. Due to the hepatotoxic characteristics, 1,4-Dichlorobenzene is applicable to liver cancer-related research.

For research use only. We do not sell to patients.

1,4-Dichlorobenzene Chemical Structure

CAS No. : 106-46-7

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
25 g	In-stock	Estimated Time of Arrival: December 31
50 g	In-stock	Estimated Time of Arrival: December 31
100 g	In-stock	Estimated Time of Arrival: December 31
> 100 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of 1,4-Dichlorobenzene:

1,4-Dichlorobenzene-d₄ In-stock
1,4-Dichlorobenzene-¹³C₆ Get quote
1,4-Dichlorobenzene (Standard) Get quote

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

1,4-dichlorobenzene undergoes hepatic cytochrome P450-mediated biotransformation with distinct profiles across male Wistar rats, male F344 rats, male B6C3F1 mice, and female B6C3F1 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

1,4-Dichlorobenzene (300-600 mg/kg/day; gavage; 5 days per week; two years) induces liver tumors (hepatocellular adenomas and carcinomas) and nonneoplastic liver lesions in male and female B6C3F₁ mice, with significant tumor increases seen at 600 mg/kg/day in both sexes and 300 mg/kg/day in males^[1].
1,4-Dichlorobenzene (150-300 mg/kg/day; gavage; 5 days per week; two years) induces a dose-related increase in renal tubular cell adenocarcinomas in male F344 rats^[1].
1,4-Dichlorobenzene (gavage; daily; 90 days) induces mitogenic liver growth and hepatocellular proliferation in male and female B6C3F₁ mice, with liver size returning to normal after compound withdrawal^[1].
1,4-Dichlorobenzene (300 ppm; inhalation; continuous; 2 years) increases the incidence of hepatocellular carcinoma and hepatoblastoma in male and female B6C3F1 mice^[2].
1,4-Dichlorobenzene (1800 mg/kg; i.g.; single dose) induces a 4.5-fold elevation in serum ALT levels in male B6C3F1 mice^[2].
1,4-Dichlorobenzene (300 mg/kg; p.o.; daily; 2 years) induces renal tubular adenocarcinoma and mononuclear cell leukemia in male F344 rats^[2].
1,4-Dichlorobenzene (600 ppm; inhalation; continuous; 13 weeks) increases the frequency of elevated serum ALT levels in male and female BDF1 mice^[2].
1,4-Dichlorobenzene (inhalation) induces hepatic cell proliferation in male and female B6C3F1 mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	B6C3F₁ mice with Liver cancer (male and female)^[1]
Dosage:	300 mg/kg/day; 600 mg/kg/day
Administration:	gavage; 5 days per week; two years
Result:	Induced significant increases in the frequency of hepatocellular carcinomas and adenomas in both male and female mice at 600 mg/kg/day. Induced an increase in hepatocellular adenomas in male mice at 300 mg/kg/day. Caused histopathological changes including hepatocellular degeneration, cell size alteration, and focal necrosis at both doses; in male mice, these nonneoplastic lesions affected over two-thirds of animals at 300 mg/kg/day.

Animal Model:	BDF₁ mice with Liver cancer (male and female)^[1]
Dosage:	20 ppm; 75 ppm; 300 ppm
Administration:	inhalation; 6 hours per day, 5 days per week; two years
Result:	Induced increases in hepatocellular carcinomas in both male and female mice, and an increase in hepatocellular adenomas in female mice at 300 ppm. Caused no increases in liver tumors at 20 ppm or 75 ppm. Induced a statistically significant 2.0-fold increase in liver weight (% body weight) relative to controls in male mice at 300 ppm. Induced a statistically significant 3.6-fold increase in liver weight (% body weight) relative to controls in female mice at 300 ppm. Caused no significant liver weight increases at 20 ppm or 75 ppm.

Molecular Weight

147.00

Formula

C₆H₄Cl₂

CAS No.

106-46-7

Appearance

Solid

Color

White to off-white

SMILES

ClC1=CC=C(Cl)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (680.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.8027 mL	34.0136 mL	68.0272 mL
5 mM	1.3605 mL	6.8027 mL	13.6054 mL
10 mM	0.6803 mL	3.4014 mL	6.8027 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (17.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (17.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (17.01 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.71%

Select Batch:

Data Sheet (276 KB) SDS (760 KB)

COA (232 KB) HNMR (224 KB) GC (257 KB)

Handling Instructions (2659 KB)

References

[1]. Butterworth BE, et al. A mechanism-based cancer risk assessment for 1,4-dichlorobenzene. Regul Toxicol Pharmacol. 2007;49(2):138-148. [Content Brief]

[2]. Hsiao PK, et al. Effects of occupational exposure to 1,4-dichlorobenzene on hematologic, kidney, and liver functions. Int Arch Occup Environ Health. 2009;82(9):1077-1085. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	6.8027 mL	34.0136 mL	68.0272 mL	170.0680 mL
	5 mM	1.3605 mL	6.8027 mL	13.6054 mL	34.0136 mL
	10 mM	0.6803 mL	3.4014 mL	6.8027 mL	17.0068 mL
	15 mM	0.4535 mL	2.2676 mL	4.5351 mL	11.3379 mL
	20 mM	0.3401 mL	1.7007 mL	3.4014 mL	8.5034 mL
	25 mM	0.2721 mL	1.3605 mL	2.7211 mL	6.8027 mL
	30 mM	0.2268 mL	1.1338 mL	2.2676 mL	5.6689 mL
	40 mM	0.1701 mL	0.8503 mL	1.7007 mL	4.2517 mL
	50 mM	0.1361 mL	0.6803 mL	1.3605 mL	3.4014 mL
	60 mM	0.1134 mL	0.5669 mL	1.1338 mL	2.8345 mL
	80 mM	0.0850 mL	0.4252 mL	0.8503 mL	2.1259 mL
	100 mM	0.0680 mL	0.3401 mL	0.6803 mL	1.7007 mL